Oncologist

Papers
(The H4-Index of Oncologist is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
37 Cost-effectiveness of treatment sequences with front-line nivolumab+ipilimumab therapy vs immuno-oncology+tyrosine kinase inhibitor therapies in intermediate/poor-risk metastatic renal cell carcino88
18 Unraveling the Impact of Tumor Microenvironment on Immunotherapy Response/Resistance in Human Sarcomatoid Clear Cell Renal Cell Carcinoma: Insights from a Novel Mouse Model84
55 Influence of gender on immunosurveillance in a novel mouse model of clear cell renal cell carcinoma79
Twenty-Year Follow-Up of a Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients With Metastatic HER2-Positive Breast Cancer77
Surgical De-Escalation in Medullary Thyroid Cancer: A Commentary71
Correction to: Physician Payments from Pharmaceutical Companies Related to Cancer Drugs68
Communicating the diagnosis of a hematological neoplastic disease to patients’ minor children: a multicenter prospective study65
The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)64
Implementation of neoadjuvant immunotherapy in stage III melanoma: a modified Delphi consensus study in a European-accredited cancer center in Ireland60
Classification of NK-large granular lymphocytic leukemia by CD56 expression57
Correction to: Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study)54
Neoadjuvant rectal-tumor regression grade combined score as surrogate endpoint for disease-free survival in locally advanced rectal cancer patients after neoadjuvant chemoradiotherapy51
46Integrated efficacy and safety exposure response (ER) analysis of tivozanib (TIVO) for the treatment of renal cell cancer (RCC)50
9Characterizing carbonic anhydrase 9 and HIF-2α RNA expression in clear cell renal cell carcinoma (ccRCC)48
IUC24430-78 Lesion-level meta-diagnostic of cognitive vs fusion MRI-targeted biopsy in PCa: PRECISION-2 insights46
Calls to action on lung cancer management and research46
IUC23530-78 Diagnostic value, safety, and patient-reported outcomes of total free-hand LATP biopsy technique46
IUC24025-78 Early results of moderate hypofractionated radiotherapy implementation for localized prostate cancer patients in Vietnam45
Cost implications of early treatment discontinuation in cancer: a real-world data analysis45
Palliative Rehabilitation in Acute Inpatient Rehabilitation: Prognostic Factors and Functional Outcomes in Patients with Cancer45
Contextualizing results of randomized trials in smoldering myeloma42
The Use of Natural Language Processing to Assess Social Support in Patients With Advanced Cancer42
Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis42
Building HOPE: operationalizing hybrid decentralized oncology clinical trials with community providers beyond traditional healthcare system networks41
Clinical ethics consultation services: public-facing information on NCI-designated cancer center websites41
8 Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: 8-year follow-up with analyses in favorable risk patients from the phase 3 CheckMate 214 trial41
Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay40
Insights of Clinical Significance From 109 695 Solid Tumor Tissue-Based Comprehensive Genomic Profiles40
Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation39
Determining the Cancer Center priorities at the Wilmot Cancer Institute: A proposed framework informed by an academic-community collaborative approach39
Survival Analysis of 1140 Patients with Biliary Cancer and Benefit from Concurrent Renin-Angiotensin Antagonists, Statins, or Aspirin with Systemic Therapy38
Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma38
Evaluating the Effectiveness of Mobile Health in Breast Cancer Care: A Systematic Review37
56 Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Relationship Confirms Best-in-class Potential of Casdatifan (AB521), a Small Molecule Inhibitor of HIF-2α Being Developed in Renal Cancer36
33Four-year survival and safety analysis from the Phase 3 TOPAZ-I study of durvalumab plus chemotherapy in biliary tract cancer36
Hypofractionated Stereotactic Re-irradiation and Anti-PDL1 Durvalumab Combination in Recurrent Glioblastoma: STERIMGLI Phase I Results36
Best therapeutic approach in metastatic hormone-sensitive prostate cancer based on disease volume: a systematic review and network meta-analysis36
Genomic landscape of malignant phyllodes tumors reveals multiple targetable opportunities36
1.5405321121216